The US Food and Drug Administration (FDA) has approved intramuscular (IM) administration of peginterferon β-1a (Plegridy, Biogen) for patients with relapsing forms of multiple sclerosis (MS). "The new ...
San Diego, California — One-year results from the phase 3 ADVANCE study suggests that peginterferon-β1a (Plegridy, Biogen Idec) has the potential to offer the efficacy and safety of currently ...
What is peginterferon alfa 2a? Peginterferon alfa 2a is an immunotherapy drug. Peginterferon alfa 2a is a possible treatment for myeloproliferative disorders such as polycythaemia vera (PV) and ...
This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major ...
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK) (known as MSD outside the United States and Canada) today announced that the U.S. Food and Drug Administration (FDA) has approved SYLATRON ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results